Skip to main content
. 2018 Jun 27;315(4):R595–R608. doi: 10.1152/ajpregu.00459.2017

Fig. 4.

Fig. 4.

Oleoylethanolamide (OEA) does not alter the hypophagic action of glucagon-like peptide-1 (GLP-1) or exendin-4 (Ex4). A–E: cumulative, 18-h food intake was measured using a PromethION metabolic cage system in lean C57BL/6J mice after intraperitoneal injection of vehicle, OEA (8 mg/kg), GLP-1 receptor agonist (GLP-1RA, 3 µg/kg), or GLP-1RA+OEA at the onset of the dark cycle and after 5 h of food deprivation. Data points reflect the means ± SE (n = 12–17/group) *vs. vehicle at same time point (P < 0.05). F–L: chow-fed C57BL/6J mice received an intracerebroventricular injection of artificial cerebrospinal fluid (ACSF, 2 µl) or 2-deoxyglucose (2-DG, 5 mM, 2 µl) followed 15 min later with intraperitoneal injection of vehicle, OEA (8 mg/kg), Ex4 (3 µg/kg), or Ex4+OEA. Data points reflect the means ± SE (n = 7–8/group). *vs. ACSF-vehicle at same time point (P < 0.05). Black and white bars represent dark and light periods, respectively.